20 Years of Pediatric Benchmarking in Germany and Austria: Age-Dependent Analysis of Longitudinal Follow-Up in 63,967 Children and Adolescents with Type 1 Diabetes

PLoS One. 2016 Aug 17;11(8):e0160971. doi: 10.1371/journal.pone.0160971. eCollection 2016.

Abstract

Background: To investigate changes in diabetes treatment over the last two decades in three age-groups of children and adolescents with type 1 diabetes (T1D) from Germany and Austria.

Methods: 63,967 subjects (<18yr) with T1D documented between 1995 and 2014 from the DPV-database were included and stratified according to age (0.5-<6, 6-<12, 12-<18yr). Regression models were applied for insulin regimens (<3 and ≥4 injection time points/day, or continuous subcutaneous insulin infusion (CSII)), use of rapid- and long acting insulin analogues, NPH insulin, and frequency of self-monitoring of blood glucose (SMBG)/day. Models were adjusted for sex, diabetes duration, and migration background. P-value for trend was given.

Findings: The number of subjects with <3 injection time points/day decreased from 1995 to 2014 to <5% in all age-groups (p<0.0001). Proportion of patients with ≥4 injections/day increased until the early 2000s, and then declined until 2014. This trend was not found in 6-<12yr olds (p = 0.3403). CSII increased in all age-groups (p<0.0001) with the highest increase in children <6 years (from 0.4% to 79.2%), and the lowest increase in 12-<18 year olds (from 1.0% to 38.9%). NPH insulin decreased in all age-groups (p<0.0001). Insulin analogues, especially rapid-acting, became more frequent in all age-groups (p<0.0001), accounting for 78.4% in 2014 for all subjects. The highest use was found in the youngest children (in 2014: 85.6%), the lowest use in 6-<12 year olds (in 2014: 72.9%). The number of SMBG/day increased from 2.2 to 6.4 with a similar rise in all age-groups (p<0.0001). Frequency was highest in subjects <6yr.

Conclusions: In all age-groups, T1D treatment was intensified over the last 20 years. Age-specific differences in trends were particularly observed in the number of patients on CSII, in the number of patients with 4 or more injections/day, and in the frequency of SMBG/day.

MeSH terms

  • Adolescent
  • Age Factors
  • Austria
  • Benchmarking
  • Blood Glucose / metabolism
  • Blood Glucose Self-Monitoring
  • Child
  • Child, Preschool
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Germany
  • Humans
  • Hypoglycemic Agents / administration & dosage*
  • Infant
  • Insulin / administration & dosage*
  • Insulin / analogs & derivatives
  • Insulin Infusion Systems / trends
  • Insulin, Long-Acting / administration & dosage
  • Longitudinal Studies
  • Male

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Insulin, Long-Acting

Grants and funding

The study was supported by the German Competence Network Diabetes mellitus (diabetes meta-database) funded by the Federal Ministry of Education and Research (FKZ 01GI1106) (https://www.bmbf.de/), now integrated into the German Center for Diabetes Research (DZD) (https://www.dzd-ev.de/) as of January 2015. Further financial support was provided by the European Foundation for the Study of Diabetes (EFSD) (http://www.europeandiabetesfoundation.org/), and by the German Diabetes Association (DDG) (http://www.deutsche-diabetes-gesellschaft.de/home.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.